Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.

Porter DL, Levine BL, Kalos M, Bagg A, June CH.

N Engl J Med. 2011 Aug 25;365(8):725-33. doi: 10.1056/NEJMoa1103849. Epub 2011 Aug 10. Erratum in: N Engl J Med. 2016 Mar 10;374(10):998.

2.

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.

Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, Teachey DT, Chew A, Hauck B, Wright JF, Milone MC, Levine BL, June CH.

N Engl J Med. 2013 Apr 18;368(16):1509-18. doi: 10.1056/NEJMoa1215134. Epub 2013 Mar 25.

3.

Chimeric antigen receptor T cells for sustained remissions in leukemia.

Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, Mahnke YD, Melenhorst JJ, Rheingold SR, Shen A, Teachey DT, Levine BL, June CH, Porter DL, Grupp SA.

N Engl J Med. 2014 Oct 16;371(16):1507-17. doi: 10.1056/NEJMoa1407222.

4.

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia.

Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, June CH.

Sci Transl Med. 2011 Aug 10;3(95):95ra73. doi: 10.1126/scitranslmed.3002842.

5.

Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia.

Imai C, Mihara K, Andreansky M, Nicholson IC, Pui CH, Geiger TL, Campana D.

Leukemia. 2004 Apr;18(4):676-84.

PMID:
14961035
6.

Chimeric antigen receptor-modified T cells in CLL.

Kochenderfer JN, Rosenberg SA.

N Engl J Med. 2011 Nov 17;365(20):1937-8; author reply 1938. doi: 10.1056/NEJMc1111004#SA2. No abstract available.

PMID:
22087695
7.

Chimeric antigen receptor-modified T cells in CLL.

Yeh CC.

N Engl J Med. 2011 Nov 17;365(20):1937; author reply 1938. doi: 10.1056/NEJMc1111004#SA1. No abstract available.

PMID:
22087694
8.

Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia.

Porter DL, Hwang WT, Frey NV, Lacey SF, Shaw PA, Loren AW, Bagg A, Marcucci KT, Shen A, Gonzalez V, Ambrose D, Grupp SA, Chew A, Zheng Z, Milone MC, Levine BL, Melenhorst JJ, June CH.

Sci Transl Med. 2015 Sep 2;7(303):303ra139. doi: 10.1126/scitranslmed.aac5415.

PMID:
26333935
9.

Redirecting T cells.

Urba WJ, Longo DL.

N Engl J Med. 2011 Aug 25;365(8):754-7. doi: 10.1056/NEJMe1106965. Epub 2011 Aug 10. No abstract available.

PMID:
21830939
10.

The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor.

Hudecek M, Schmitt TM, Baskar S, Lupo-Stanghellini MT, Nishida T, Yamamoto TN, Bleakley M, Turtle CJ, Chang WC, Greisman HA, Wood B, Maloney DG, Jensen MC, Rader C, Riddell SR.

Blood. 2010 Nov 25;116(22):4532-41. doi: 10.1182/blood-2010-05-283309. Epub 2010 Aug 11.

11.

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.

Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, Fry TJ, Orentas R, Sabatino M, Shah NN, Steinberg SM, Stroncek D, Tschernia N, Yuan C, Zhang H, Zhang L, Rosenberg SA, Wayne AS, Mackall CL.

Lancet. 2015 Feb 7;385(9967):517-28. doi: 10.1016/S0140-6736(14)61403-3. Epub 2014 Oct 13.

PMID:
25319501
12.

Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation.

Kochenderfer JN, Dudley ME, Carpenter RO, Kassim SH, Rose JJ, Telford WG, Hakim FT, Halverson DC, Fowler DH, Hardy NM, Mato AR, Hickstein DD, Gea-Banacloche JC, Pavletic SZ, Sportes C, Maric I, Feldman SA, Hansen BG, Wilder JS, Blacklock-Schuver B, Jena B, Bishop MR, Gress RE, Rosenberg SA.

Blood. 2013 Dec 12;122(25):4129-39. doi: 10.1182/blood-2013-08-519413. Epub 2013 Sep 20.

13.

[Treatment of lymphoblastic leukemia with CD19-specific modified chimeric antigen receptor T cells].

Li HH, Zhu P, Wu XQ, Liu YF.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014 Dec;22(6):1753-6. doi: 10.7534/j.issn.1009-2137.2014.06.047. Review. Chinese.

PMID:
25543510
14.

How to train your T cell: genetically engineered chimeric antigen receptor T cells versus bispecific T-cell engagers to target CD19 in B acute lymphoblastic leukemia.

Ruella M, Gill S.

Expert Opin Biol Ther. 2015 Jun;15(6):761-6. doi: 10.1517/14712598.2015.1009888. Epub 2015 Feb 2.

PMID:
25640460
15.

Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor.

Kochenderfer JN, Feldman SA, Zhao Y, Xu H, Black MA, Morgan RA, Wilson WH, Rosenberg SA.

J Immunother. 2009 Sep;32(7):689-702. doi: 10.1097/CJI.0b013e3181ac6138.

16.

Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells.

Loskog A, Giandomenico V, Rossig C, Pule M, Dotti G, Brenner MK.

Leukemia. 2006 Oct;20(10):1819-28. Epub 2006 Aug 17.

PMID:
16932339
17.
18.

Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.

Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, Stetler-Stevenson M, Yang JC, Phan GQ, Hughes MS, Sherry RM, Raffeld M, Feldman S, Lu L, Li YF, Ngo LT, Goy A, Feldman T, Spaner DE, Wang ML, Chen CC, Kranick SM, Nath A, Nathan DA, Morton KE, Toomey MA, Rosenberg SA.

J Clin Oncol. 2015 Feb 20;33(6):540-9. doi: 10.1200/JCO.2014.56.2025. Epub 2014 Aug 25.

19.

Low-cost generation of Good Manufacturing Practice-grade CD19-specific chimeric antigen receptor-expressing T cells using piggyBac gene transfer and patient-derived materials.

Ramanayake S, Bilmon I, Bishop D, Dubosq MC, Blyth E, Clancy L, Gottlieb D, Micklethwaite K.

Cytotherapy. 2015 Sep;17(9):1251-67. doi: 10.1016/j.jcyt.2015.05.013. Epub 2015 Jul 23.

PMID:
26212611
20.

4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies.

Tammana S, Huang X, Wong M, Milone MC, Ma L, Levine BL, June CH, Wagner JE, Blazar BR, Zhou X.

Hum Gene Ther. 2010 Jan;21(1):75-86. doi: 10.1089/hum.2009.122.

Supplemental Content

Support Center